Gartler found that many of the varied cell lines he was ordering from biological suppliers were testing positive for a specific ... itself — Henrietta had HPV-18, a particularly nasty form ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell ...

EcDNA is made up of small, circular segments of DNA that form outside of chromosomes within the cell ... integration of HPV genes and human DNA is present in about 30% of HPV-positive ...

Overall, the results showed that HPV-positive patients had a 40% higher likelihood of developing cardiovascular disease and twice the risk of developing coronary artery disease compared with HPV ...

Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; ...

The combination therapy is intended for use as a first-line treatment ... HPV16-positive head and neck squamous cell cancers ...

The abstracts will showcase research on Versamune® HPV (PDS0101), particularly its effectiveness in treating HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma in ...

BioAtla Inc (BCAB) showcases significant advancements in clinical trials while navigating financial hurdles and seeking strategic partnerships.

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead ...